Strongbridge Biopharma plc (SBBP) Stock Rating Lowered by Zacks Investment Research
Strongbridge Biopharma plc (NASDAQ:SBBP) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research note issued on Wednesday.
According to Zacks, “Strongbridge Biopharma PLC is a biopharmaceutical company which develops, acquires and commercializes product candidates that target rare diseases. Its product candidate consists of COR-003, is a cortisol inhibitor, for the treatment of endogenous Cushing’s syndrome, COR-004 and COR-005 to treat acromegaly, BP-2001, the treatment of diabetes which are in different clinical trial. Strongbridge Biopharma PLC is based in Trevose, Pennsylvania. “
Separately, HC Wainwright increased their target price on shares of Strongbridge Biopharma plc from $15.00 to $18.00 and gave the company a “buy” rating in a research report on Wednesday, January 25th.
Strongbridge Biopharma plc (NASDAQ:SBBP) opened at 4.60 on Wednesday. The stock’s market capitalization is $162.54 million. The company’s 50-day moving average is $4.35 and its 200 day moving average is $3.56. Strongbridge Biopharma plc has a 1-year low of $2.00 and a 1-year high of $6.24.
Strongbridge Biopharma plc (NASDAQ:SBBP) last issued its earnings results on Tuesday, May 16th. The biotechnology company reported ($0.33) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.49) by $0.16. Equities analysts predict that Strongbridge Biopharma plc will post ($2.11) earnings per share for the current year.
Several large investors have recently modified their holdings of SBBP. Boxer Capital LLC acquired a new stake in shares of Strongbridge Biopharma plc during the fourth quarter worth approximately $2,256,000. Opaleye Management Inc. acquired a new stake in shares of Strongbridge Biopharma plc during the fourth quarter worth approximately $2,784,000. Broadfin Capital LLC boosted its stake in shares of Strongbridge Biopharma plc by 74.7% in the fourth quarter. Broadfin Capital LLC now owns 2,894,581 shares of the biotechnology company’s stock worth $6,947,000 after buying an additional 1,237,875 shares during the period. Finally, Vivo Capital LLC acquired a new stake in shares of Strongbridge Biopharma plc during the fourth quarter worth approximately $7,200,000. Institutional investors and hedge funds own 42.86% of the company’s stock.
Strongbridge Biopharma plc Company Profile
Strongbridge Biopharma plc is a global commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies for a range of diseases. The Company’s commercial product, KEVEYIS (dichlorphenamide), is indicated for the treatment of hyperkalemic, hypokalemic and related variants of primary periodic paralysis.
Receive News & Stock Ratings for Strongbridge Biopharma plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Strongbridge Biopharma plc and related stocks with our FREE daily email newsletter.